Gemcitabine Injection, Solution
Product Images NDC 25021-239

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 25021-239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gem0a 0007 01

FDA Label Image

Gem0a 0007 02

FDA Label Image

Gem0a 0007 03

This text appears to be discussing a comparison of documented disease progression between two treatments over a certain period. It includes information about the number of months for each treatment group (Paciiaxel 29 months) and presents statistical results (Log rank p 00001) indicating a significant difference. The study involves a comparison of Gemcitabine/Paciiaxel treatment with a group of 267 participants. The x-axis appears to be "Time to Documented Disease Progression (Months)."*

FDA Label Image

Gem0a 0007 04

This text provides information on survival rates related to Gem/Cis and Cisplatin treatments. The median survival times are 9.0 months for Gem/Cis and 7.6 months for Cis. The text also mentions survival probabilities but includes incomplete data. Overall, this document serves as a guide for understanding survival outcomes for cancer patients undergoing these treatments.*

FDA Label Image

Gem0a 0007 05

FDA Label Image

Gem0a 0007 06

FDA Label Image

Gem0a 0007 07

FDA Label Image

Gem0a 0007 08

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.